| Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449) |
|---|
| 01/13/2005 | WO2005002508A2 Macromolecular platinum chelates |
| 01/13/2005 | WO2005002507A2 Modulation of survivin expression |
| 01/13/2005 | WO2005002506A2 Method for treating diseases using hsp90-inhibiting agents in combination with antimetabolites |
| 01/13/2005 | WO2005002505A2 Apolipoprotein c-1 induced apoptosis |
| 01/13/2005 | WO2005002504A2 Protection against vertical transmission of pathogenic infections |
| 01/13/2005 | WO2005002503A2 Asymmetric benzimidazoles and related compounds as potassium channel modulators |
| 01/13/2005 | WO2005002502A2 An assay for detecting the presence of processing inhibitory antibodies against the apical membrane antigene-1 of plasmodium falciparum in biological samples |
| 01/13/2005 | WO2005002501A2 Novel druggable regions in the dengue virus envelope glycoprotein and methods of using the same |
| 01/13/2005 | WO2005002500A2 Inhibitors of coronavirus |
| 01/13/2005 | WO2005002499A2 A method and therapeutic platelets |
| 01/13/2005 | WO2005002498A2 Methods of treating disorders caused by formation of transcripts carrying nonsense mutations |
| 01/13/2005 | WO2005002496A2 Method of obtaining taxosteroids and precursors thereof |
| 01/13/2005 | WO2004098523A3 Intraocular brachytherapy device and method |
| 01/13/2005 | WO2004073654A3 A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained supression of gastric acid |
| 01/13/2005 | WO2004069191A3 Identification of t1r and t2r modulators |
| 01/13/2005 | WO2004024097A8 Compositions and methods for the treatment of immune related diseases |
| 01/13/2005 | WO2003092609A9 System and method of treating abnormal tissue in an organ having a layered tissue structure |
| 01/13/2005 | US20050009920 Taxol enhancer compounds |
| 01/13/2005 | US20050009895 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors |
| 01/13/2005 | US20050009885 Administering the dihydropyridine calcium channel antagonist, nilvadipine to treat a cerebral amyloidogenic disease, such as Alzheimer's disease, transmissible spongiform encephalopathy, scrapie, traumatic brain injury, cerebral amyloid angiopathy and Gerstmann-Straussler-Scheinker syndrome |
| 01/13/2005 | US20050009870 3-(amino)sulfonylamino-substituted, e.g., N-(1,6-Dibenzyl-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide and N-(1-Benzyl-2-oxo-6-(thiophen-3-yl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide; eating, metabolic, obesity, cognitive, neurological, pain, inflammatory and psychiatric disorders |
| 01/13/2005 | US20050009862 Method for promoting uninterrupted sleep by administration of trospium chloride |
| 01/13/2005 | US20050009840 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer |
| 01/13/2005 | US20050009786 Immunosuppressant compounds and compositions |
| 01/13/2005 | US20050009773 Synergistic treatment of cancer using immunomers in conjunction with therapeutic agents |
| 01/13/2005 | US20050009740 Mixture of carrier, target peptide and immune response triggers |
| 01/13/2005 | US20050009150 Humanized antibodies that recognize beta amyloid peptide |
| 01/13/2005 | US20050009137 Intracellular estradiol binding protein, a polynucleotide encoding the same and cell lines overexpressing the same |
| 01/13/2005 | US20050009057 Using apical membrane antigen-1 as a diagnostic and therapeutic aide in treatment and prevention of plasmodium infection; immunotherapy; antimalarial agents |
| 01/13/2005 | US20050008640 Method of treating transplant rejection |
| 01/13/2005 | US20050008634 Parenteral formulations of peptides for the treatment of systemic lupus erythematosus |
| 01/13/2005 | US20050008615 Conjugates comprising human IL-18 and substitution mutants thereof |
| 01/13/2005 | US20050008613 Immobilized on solid carrier; reducing concentration of microbiocides; water purification; foods |
| 01/13/2005 | US20050008584 Solid drug in water insoluble carrier; drug delivery pen or crayon; teeth whitening; containing sodium percarbonate |
| 01/13/2005 | US20050008580 Hemophilia treatment by inhalation of coagulation factors |
| 01/13/2005 | CA2530808A1 Cox-2 and faah inhibitors |
| 01/13/2005 | CA2530594A1 Methods for treating and preventing cardiac arrhythmia |
| 01/13/2005 | CA2530081A1 Ophthalmic compositions for treating ocular hypertension |
| 01/13/2005 | CA2530032A1 Deployable multifunctional hemostatic agent |
| 01/13/2005 | CA2529555A1 Leukocyte internalized peptide-drug conjugates |
| 01/13/2005 | CA2528094A1 Expression vectors for stimulating an immune response to cancer antigens |
| 01/13/2005 | CA2525580A1 Asymmetric benzimidazoles and related compounds as potassium channel modulators |
| 01/13/2005 | CA2525236A1 Delivery of therapeutic compounds to the brain and other tissues |
| 01/13/2005 | CA2524495A1 Modulation of survivin expression |
| 01/13/2005 | CA2522329A1 Inhibitors of coronavirus |
| 01/13/2005 | CA2520224A1 Immunogenicity-reduced anti-cr1 antibody and compositions and methods of treatment based thereon |
| 01/12/2005 | EP1496060A1 Antitumoral analogs of ET-743 |
| 01/12/2005 | EP1495122A1 Antiviral therapy on the basis of rna interference |
| 01/12/2005 | EP0991628B1 QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56lck TYROSINE KINASES |
| 01/12/2005 | CN1564683A Methods for treating dry eye by a combination of an antiinflammatory steroid and a MUC-1 secretagogue |
| 01/12/2005 | CN1184208C Substituted benzimidazoles and their prepn. and use |
| 01/12/2005 | CN1183900C Nicotine inhaler |
| 01/11/2005 | US6841698 Aminopropylphosphinic acids |
| 01/11/2005 | US6840964 Oxidation dyeing method using N-acetyclysteine as a reducing agent and laccase as an oxidating agent |
| 01/11/2005 | US6840244 Condom with an erectogenic composition |
| 01/06/2005 | WO2005000250A2 Imaging agents and methods of imaging alpha 7-nicotinic cholinergic receptor |
| 01/06/2005 | WO2005000249A2 Preparation of chemical compounds |
| 01/06/2005 | WO2005000248A2 Compositions and methods for skin conditioning |
| 01/06/2005 | WO2005000247A2 4-carboxamido quinoline derivatives for use as nk-2 and nk-3 |
| 01/06/2005 | WO2005000246A2 Methods and compositions for treating rheumatoid arthritis |
| 01/06/2005 | WO2005000245A2 Compositions and methods for increasing telomerase activity |
| 01/06/2005 | WO2005000244A2 Methods and compositions for treating rheumatoid arthritis |
| 01/06/2005 | WO2005000243A2 The polymorphic form a of 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butryric acid |
| 01/06/2005 | WO2005000241A2 Compositons and methods for topical administration |
| 01/06/2005 | WO2005000240A2 Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis |
| 01/06/2005 | WO2005000239A2 Lyase treatment for p. carinii |
| 01/06/2005 | WO2005000238A2 Use of selective cyclooxygenase-2 inhibitors for the treatment of endometriosis |
| 01/06/2005 | WO2005000237A2 Granules containing biologically active substances |
| 01/06/2005 | WO2005000235A2 NUCLEIC ACID SEQUENCES ENCODING AND COMPOSITIONS COMPRISING IgE SIGNAL PEPTIDE AND/OR IL-15 AND METHODS FOR USING THE SAME |
| 01/06/2005 | WO2005000234A2 Novel coronavirus inhibitors |
| 01/06/2005 | WO2005000233A2 Novel therapeautic agents for the treatment of cancer, metabolic diseases and skin disorders |
| 01/06/2005 | WO2005000231A2 Il-8 receptor antagonists |
| 01/06/2005 | WO2005000230A2 Methods of treating hyperproliferative cell disorders |
| 01/06/2005 | WO2005000229A2 Compositions and methods for modulating s-nitrosoglutathione reductase |
| 01/06/2005 | WO2005000228A2 Synthesis of labeled oxalic acid derivatives |
| 01/06/2005 | WO2005000227A2 Methods of treating tnf-mediated disorders |
| 01/06/2005 | WO2005000226A2 Mixed bed multi-dimensional chromatography systems and methods of making and using them |
| 01/06/2005 | WO2005000225A2 Production of rabies antibodies in plants |
| 01/06/2005 | WO2005000223A2 Method of treating retinopathies and disorders associated with blood vessel loss |
| 01/06/2005 | WO2005000222A2 Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins |
| 01/06/2005 | WO2005000220A2 Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes |
| 01/06/2005 | WO2005000219A2 Composition for blocking hiv binding to dendritic cells and methods of use thereof |
| 01/06/2005 | WO2005000218A2 Macrocyclic cyanine and indocyanine bioconjugates provide improved biomedical applications |
| 01/06/2005 | WO2005000217A2 Combination therapy for the treatment of dyslipidemia |
| 01/06/2005 | WO2005000216A2 Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders |
| 01/06/2005 | WO2005000215A2 Methods for treating pain |
| 01/06/2005 | WO2005000214A2 Method for treating diseases using hsp90-inhibiting agents in combination with antibiotics |
| 01/06/2005 | WO2005000213A2 Method for treating diseases using hsp90-inhibiting agents in combination with enzyme inhibitors |
| 01/06/2005 | WO2005000212A2 Method for treating diseases using hsp90-inhibiting agents in combination with nuclear export inhibitors |
| 01/06/2005 | WO2005000211A2 Method for treating diseases using hsp90-inhibiting agents in combination with platinum coordination complexes |
| 01/06/2005 | WO2005000210A2 Synthesis of high molecular weight iron-saccharidic complexes |
| 01/06/2005 | WO2005000209A2 An improved method and apparatus for dosing single and multi-agent therapy |
| 01/06/2005 | WO2005000208A2 Combination therapy for the treatment of neoplasms |
| 01/06/2005 | WO2005000207A2 Pcdgf receptor antibodies and methods of use thereof |
| 01/06/2005 | WO2005000205A2 Methods and compositions for modulating serum cortisol levels |
| 01/06/2005 | WO2005000204A2 Pancreatic cancer treatment |
| 01/06/2005 | WO2005000203A2 Methods for treating cognitive impairment and improving cognition |
| 01/06/2005 | WO2005000202A2 Compositions and methods for the modulation of the expression of b7 protein |
| 01/06/2005 | WO2005000201A2 Modulation of apolipoprotein (a) expression |
| 01/06/2005 | WO2005000200A2 Novel kinases |